{"id":59248,"date":"2026-03-11T13:49:04","date_gmt":"2026-03-11T05:49:04","guid":{"rendered":"https:\/\/flcube.com\/?p=59248"},"modified":"2026-03-11T13:49:04","modified_gmt":"2026-03-11T05:49:04","slug":"hightide-therapeutics-htd1801-nda-accepted-by-nmpa-first-in-class-ampk-nlrp3-dual-target-drug-for-type-2-diabetes","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59248","title":{"rendered":"HighTide Therapeutics&#8217; HTD1801 NDA Accepted by NMPA \u2013 First-in-Class AMPK\/NLRP3 Dual-Target Drug for Type 2 Diabetes"},"content":{"rendered":"\n<p><strong>HighTide Therapeutics Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2511:HKG\">HKG: 2511<\/a>) announced that China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has <strong>accepted the New Drug Application (NDA)<\/strong> for <strong>HTD1801<\/strong> for the treatment of <strong>type 2 diabetes mellitus (T2DM)<\/strong>. The milestone marks <strong>HighTide&#8217;s first NDA submission<\/strong> and represents a <strong>significant step toward commercialization<\/strong> for the <strong>globally first-in-class oral anti-inflammatory and metabolic modulator (AIMM)<\/strong> that targets <strong>cardiorenal metabolic (CKM) diseases<\/strong> through a <strong>unique dual mechanism<\/strong> activating <strong>AMPK<\/strong> while inhibiting the <strong>NLRP3 inflammasome<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>National Medical Products Administration (NMPA)<\/td><\/tr><tr><td><strong>Filing Type<\/strong><\/td><td>New Drug Application (NDA)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>HTD1801<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Oral anti-inflammatory and metabolic modulator (AIMM) \u2013 first-in-class globally<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Dual-target: AMPK activation + NLRP3 inflammasome inhibition<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Type 2 diabetes mellitus (T2DM)<\/td><\/tr><tr><td><strong>Developer<\/strong><\/td><td>HighTide Therapeutics Inc. (HKG: 2511)<\/td><\/tr><tr><td><strong>Significance<\/strong><\/td><td>First NDA submission for HighTide; entry into product commercialization phase<\/td><\/tr><tr><td><strong>Acceptance Date<\/strong><\/td><td>10\u202fMar\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism\">Drug Profile &amp; Mechanism<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>HTD1801 Specification<\/th><\/tr><\/thead><tbody><tr><td><strong>Novelty<\/strong><\/td><td>Globally first-in-class new molecular entity (NME)<\/td><\/tr><tr><td><strong>Primary Mechanism<\/strong><\/td><td><strong>AMPK activation<\/strong> \u2013 master regulator of cellular energy metabolism; improves insulin sensitivity, glucose uptake, mitochondrial function<\/td><\/tr><tr><td><strong>Secondary Mechanism<\/strong><\/td><td><strong>NLRP3 inflammasome inhibition<\/strong> \u2013 suppresses pro-inflammatory cytokine release (IL-1\u03b2, IL-18); addresses meta-inflammation in T2DM<\/td><\/tr><tr><td><strong>Dual-Action Synergy<\/strong><\/td><td>Complementary metabolic and anti-inflammatory effects; addresses root causes of cardiorenal metabolic dysfunction<\/td><\/tr><tr><td><strong>Route<\/strong><\/td><td>Oral administration<\/td><\/tr><tr><td><strong>Therapeutic Focus<\/strong><\/td><td>Cardiorenal metabolic (CKM) system diseases \u2013 T2DM, with potential expansion to NASH, CKD, CVD<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Scientific Rationale:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>AMPK Pathway:<\/strong> Restores metabolic homeostasis; enhances insulin signaling; promotes fatty acid oxidation<\/li>\n\n\n\n<li><strong>NLRP3 Inflammasome:<\/strong> Chronic activation drives insulin resistance, beta-cell dysfunction, and vascular inflammation<\/li>\n\n\n\n<li><strong>Synergy:<\/strong> Simultaneous targeting addresses both metabolic and inflammatory components of T2DM pathophysiology<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-context-amp-market-opportunity\">Strategic Context &amp; Market Opportunity<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>China T2D Market<\/strong><\/td><td>140+ million diagnosed patients; largest global population; unmet need for disease-modifying therapies beyond glucose control<\/td><\/tr><tr><td><strong>Metformin Dominance<\/strong><\/td><td>First-line standard with limitations; HTD1801 offers mechanistic differentiation for combination or alternative use<\/td><\/tr><tr><td><strong>Cardiorenal Protection<\/strong><\/td><td>AMPK\/NLRP3 dual targeting may provide kidney and cardiovascular benefits \u2013 critical for T2DM patient outcomes<\/td><\/tr><tr><td><strong>First-in-Class Positioning<\/strong><\/td><td>No approved AMPK\/NLRP3 dual modulators globally; potential for premium pricing and rapid formulary access<\/td><\/tr><tr><td><strong>Pipeline Expansion<\/strong><\/td><td>CKM focus enables label expansion to NASH (non-alcoholic steatohepatitis) and CKD (chronic kidney disease)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Competitor<\/th><th>Product<\/th><th>Mechanism<\/th><th>Status<\/th><th>HTD1801 Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>Metformin<\/strong><\/td><td>Glucophage<\/td><td>AMPK activation (indirect)<\/td><td>Generic first-line<\/td><td>Direct, potent AMPK activation + NLRP3 inhibition<\/td><\/tr><tr><td><strong>Novo Nordisk<\/strong><\/td><td>Ozempic (semaglutide)<\/td><td>GLP-1R agonist<\/td><td>Approved (T2D, obesity)<\/td><td>Oral convenience; potential cardiorenal synergy with GLP-1<\/td><\/tr><tr><td><strong>Eli Lilly<\/strong><\/td><td>Mounjaro (tirzepatide)<\/td><td>GIPR\/GLP-1R dual agonist<\/td><td>Approved (T2D)<\/td><td>Mechanistic complementarity; potential combination<\/td><\/tr><tr><td><strong>HighTide<\/strong><\/td><td><strong>HTD1801<\/strong><\/td><td><strong>AMPK + NLRP3 dual modulator<\/strong><\/td><td><strong>NDA accepted<\/strong><\/td><td><strong>First-in-class; addresses meta-inflammation; CKM pipeline potential<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-amp-commercial-outlook\">Development &amp; Commercial Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Timeline<\/th><th>Objectives<\/th><\/tr><\/thead><tbody><tr><td><strong>NDA Review<\/strong><\/td><td>2026-2027<\/td><td>NMPA technical and clinical review; manufacturing inspection<\/td><\/tr><tr><td><strong>Approval<\/strong><\/td><td>Q4 2026 \u2013 Q1 2027<\/td><td>Conditional or full approval anticipated<\/td><\/tr><tr><td><strong>Commercial Launch<\/strong><\/td><td>2027<\/td><td>Hospital formulary access; endocrinologist education; NRDL negotiation<\/td><\/tr><tr><td><strong>Label Expansion<\/strong><\/td><td>2027-2029<\/td><td>NASH Phase II\/III; CKD indication development<\/td><\/tr><tr><td><strong>Global Strategy<\/strong><\/td><td>2027+<\/td><td>U.S.\/EU IND filing; partnership discussions for ex-China rights<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding NDA review timelines, regulatory approval, and commercial positioning for HTD1801. Actual results may differ due to NMPA review delays, competitive dynamics with incretin therapies, and manufacturing scale-up challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>HighTide Therapeutics Inc. (HKG: 2511) announced that China&#8217;s National Medical Products Administration (NMPA) has accepted&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[39,610,1309,38],"class_list":["post-59248","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-diabetes","tag-hightide-therapeutics","tag-hkg-2511","tag-market-approval-filings"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>HighTide Therapeutics&#039; HTD1801 NDA Accepted by NMPA \u2013 First-in-Class AMPK\/NLRP3 Dual-Target Drug for Type 2 Diabetes - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"HighTide Therapeutics Inc. (HKG: 2511) announced that China&#039;s National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for HTD1801 for the treatment of type 2 diabetes mellitus (T2DM). The milestone marks HighTide&#039;s first NDA submission and represents a significant step toward commercialization for the globally first-in-class oral anti-inflammatory and metabolic modulator (AIMM) that targets cardiorenal metabolic (CKM) diseases through a unique dual mechanism activating AMPK while inhibiting the NLRP3 inflammasome.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59248\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HighTide Therapeutics&#039; HTD1801 NDA Accepted by NMPA \u2013 First-in-Class AMPK\/NLRP3 Dual-Target Drug for Type 2 Diabetes\" \/>\n<meta property=\"og:description\" content=\"HighTide Therapeutics Inc. (HKG: 2511) announced that China&#039;s National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for HTD1801 for the treatment of type 2 diabetes mellitus (T2DM). The milestone marks HighTide&#039;s first NDA submission and represents a significant step toward commercialization for the globally first-in-class oral anti-inflammatory and metabolic modulator (AIMM) that targets cardiorenal metabolic (CKM) diseases through a unique dual mechanism activating AMPK while inhibiting the NLRP3 inflammasome.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59248\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-11T05:49:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59248#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59248\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"HighTide Therapeutics&#8217; HTD1801 NDA Accepted by NMPA \u2013 First-in-Class AMPK\\\/NLRP3 Dual-Target Drug for Type 2 Diabetes\",\"datePublished\":\"2026-03-11T05:49:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59248\"},\"wordCount\":526,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Diabetes\",\"HighTide Therapeutics\",\"HKG: 2511\",\"Market approval filings\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59248#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59248\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59248\",\"name\":\"HighTide Therapeutics' HTD1801 NDA Accepted by NMPA \u2013 First-in-Class AMPK\\\/NLRP3 Dual-Target Drug for Type 2 Diabetes - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-11T05:49:04+00:00\",\"description\":\"HighTide Therapeutics Inc. (HKG: 2511) announced that China's National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for HTD1801 for the treatment of type 2 diabetes mellitus (T2DM). The milestone marks HighTide's first NDA submission and represents a significant step toward commercialization for the globally first-in-class oral anti-inflammatory and metabolic modulator (AIMM) that targets cardiorenal metabolic (CKM) diseases through a unique dual mechanism activating AMPK while inhibiting the NLRP3 inflammasome.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59248#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59248\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59248#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HighTide Therapeutics&#8217; HTD1801 NDA Accepted by NMPA \u2013 First-in-Class AMPK\\\/NLRP3 Dual-Target Drug for Type 2 Diabetes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"HighTide Therapeutics' HTD1801 NDA Accepted by NMPA \u2013 First-in-Class AMPK\/NLRP3 Dual-Target Drug for Type 2 Diabetes - Insight, China&#039;s Pharmaceutical Industry","description":"HighTide Therapeutics Inc. (HKG: 2511) announced that China's National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for HTD1801 for the treatment of type 2 diabetes mellitus (T2DM). The milestone marks HighTide's first NDA submission and represents a significant step toward commercialization for the globally first-in-class oral anti-inflammatory and metabolic modulator (AIMM) that targets cardiorenal metabolic (CKM) diseases through a unique dual mechanism activating AMPK while inhibiting the NLRP3 inflammasome.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59248","og_locale":"en_US","og_type":"article","og_title":"HighTide Therapeutics' HTD1801 NDA Accepted by NMPA \u2013 First-in-Class AMPK\/NLRP3 Dual-Target Drug for Type 2 Diabetes","og_description":"HighTide Therapeutics Inc. (HKG: 2511) announced that China's National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for HTD1801 for the treatment of type 2 diabetes mellitus (T2DM). The milestone marks HighTide's first NDA submission and represents a significant step toward commercialization for the globally first-in-class oral anti-inflammatory and metabolic modulator (AIMM) that targets cardiorenal metabolic (CKM) diseases through a unique dual mechanism activating AMPK while inhibiting the NLRP3 inflammasome.","og_url":"https:\/\/flcube.com\/?p=59248","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-11T05:49:04+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59248#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59248"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"HighTide Therapeutics&#8217; HTD1801 NDA Accepted by NMPA \u2013 First-in-Class AMPK\/NLRP3 Dual-Target Drug for Type 2 Diabetes","datePublished":"2026-03-11T05:49:04+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59248"},"wordCount":526,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Diabetes","HighTide Therapeutics","HKG: 2511","Market approval filings"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59248#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59248","url":"https:\/\/flcube.com\/?p=59248","name":"HighTide Therapeutics' HTD1801 NDA Accepted by NMPA \u2013 First-in-Class AMPK\/NLRP3 Dual-Target Drug for Type 2 Diabetes - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-11T05:49:04+00:00","description":"HighTide Therapeutics Inc. (HKG: 2511) announced that China's National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for HTD1801 for the treatment of type 2 diabetes mellitus (T2DM). The milestone marks HighTide's first NDA submission and represents a significant step toward commercialization for the globally first-in-class oral anti-inflammatory and metabolic modulator (AIMM) that targets cardiorenal metabolic (CKM) diseases through a unique dual mechanism activating AMPK while inhibiting the NLRP3 inflammasome.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59248#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59248"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59248#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"HighTide Therapeutics&#8217; HTD1801 NDA Accepted by NMPA \u2013 First-in-Class AMPK\/NLRP3 Dual-Target Drug for Type 2 Diabetes"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59248","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59248"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59248\/revisions"}],"predecessor-version":[{"id":59250,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59248\/revisions\/59250"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59248"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59248"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59248"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}